Cardiovascular events after the initiation of immune checkpoint inhibitors

Cardiovascular events after the initiation of immune checkpoint inhibitors

We sought to clarify the incidence of major adverse cardiac events (MACE) after the initiation of immune checkpoint inhibitors (ICIs). We analyzed the JMDC Claims Database between 2005 and 2021. The study included 2972 patients with no history of cardiovascular disease and a prescription for an ICI....

Full description

Bibliographic Details
Main Authors: Yuta Suzuki, Hidehiro Kaneko, Yuichi Tamura, Akira Okada, Katsuhito Fujiu, Nobuaki Michihata, Norifumi Takeda, Taisuke Jo, Hiroyuki Morita, Koichi Node, Hideo Yasunaga, Issei Komuro
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Heliyon
Subjects:
Cancer
Immune checkpoint inhibitors
Immune-related adverse events
Cardiovascular disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844023035806

Internet

http://www.sciencedirect.com/science/article/pii/S2405844023035806

Similar Items